Treatment of lipids and type 2 diabetes

Current Cardiology Reports

Volumn 6, Issue 6, 2004, Pages 443-450

  Hermayer, Kathie L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EPIDEMIC; FLUSHING; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MUSCLE DISEASE; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SKIN MANIFESTATION; VASCULAR DISEASE;

EID: 9744223641     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0053-4     Document Type: Review

References (51)

1. American Diabetes Association: Basic Diabetes Information. Facts and Figures. The Impact of Diabetes. http://www.diabetes.org
2. Haffner SM, Goldberg RB: New strategies for the treatment of diabetic dyslipidemia. Diabetes Care 2002, 25: 237-1239.
3. American Diabetes Association: Dyslipidemia management in adults with diabetes (position statement). Diabetes Care 2004, 27:S68-S71.
4. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute. Circulation 2002, 106:3143-3234.
5. O'Brien T, Nguyen TD, Zimmerman BR: Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998, 73:969-976.
6. Plan and operation of the Third National Health and Nutrition examination survey, 1988-1994. Series 1: progress and collection procedures. Vital Health Statistics 1994, 1: -407.
7. Siegal RD, Cupples A, Schaefer, EJ, et al.: Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996, 45:1267-1272.
8. Haffner SM: Lipoprotein (a) and diabetes. An update. Diabetes Care 1993, 16:835-840.
9. Bucala R, Makita Z, Vega G, et al.: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994, 91:9441-9445.
10. Henry RR: Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clin Diabetes 2001, 19:113-120.
11. Wilson PWF, D'Agostino RB, Levy D, et al.: Prediction ot coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
12. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals. Lancet 2002, 360:7-22.
13. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial: Lancet 2003, 361:2005-2016.
14. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texsas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 615-1622.
15. Snow V, Aronson MD, Hornblake ER, et al.: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004, 140:644-E650.
16. Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004, 140: 650-658.
17. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
18. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987, 317: 237-1245.
19. Shepard J, Blauw GJ, Murphy MD, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623-1630.
20. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-Scandinavian Cardiac outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003, 361: 149-1158.
21. Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
22. Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159, 1259:2661-2667.
23. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
24. Sacks FM, Tonkin AM, Craven T, et al.: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105: 424-1428.
25. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
26. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
27. Serruys PW, Feyter P, Macaya C, et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002, 287:3215-3222.
28. Hoogwerf BJ, Waness A, Cressman M, et al.: Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. Diabetes 1999, 48:1289-1294.
29. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
30. Lamarche B, Tchernof A, Moorjani S, et al.: Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
31. Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
32. Brunzell JD, Ayyobi AF: Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003, 115: 4S-28S.
33. Buse J: Statin treatment in diabetes mellitus. Clin Diabetes 2003, 21:168-172.
34. Sen K, Misra A, Kumer A, et al.: Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002, 56: -11.
35. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 2002, 53:493-502.
36. Fried LF, Forrest KY, Ellis D, et al.: Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complication 2001, 15: 13-119.
37. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
38. Furburg CD, Pitt B: Withdrawal of cervistatin from the world market. Curr Control Trials Cardiovasc Med 2001, 2: 05-207.
39. Athyros BG, Papageorgiou AA, Athyrou VV, et al.: Atorvastatin and micronized fenofibrate, alone and in combination, in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
40. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990, 264:723-726.
41. Elam MD, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
42. Grundy SM, Vega GL, McGovern ME, et al.: Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002, 162:1568-1576.
43. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994, 121:416-422.
44. Vessby B, Boberg M: Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1990, 228:165-171.
45. Dujovne CA, Ettinger MP, McNeer JF, et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092-1097.
46. Gagno C, Bays HE, Weiss SR, et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
47. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet 2000, 355:253-259.
48. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with zconventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
49. UK Prospective Diabetes study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352: 54-865.
50. American Diabetes Association: Physical activity/exercise and diabetes (position statement). Diabetes Care 2004, 27: 58-S62.
51. Chandalia M, Garg A, Lutjohann D, et al.: Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000, 342:1392-1398.